Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Angiopoietin-2 predicts prognosis in lung cancer

09 Oct 2017
Lung cancer patients have new hope thanks to an experimental treatment has been proven to be more effective

Serum concentrations of angiopoietin-2 (Ang-2) appear to predict the tumour staging and prognosis of patients with lung cancer, according to a new systematic review and meta-analysis.

After the selection criteria were applied, 20 studies, corresponding to 1,911 patients, were eligible for inclusion. Of these, the nine that evaluated the relationship between Ang-2 levels and disease progression showed a positive significant association between serum Ang-2 levels and tumour stage.

Specifically, a significant difference in Ang-2 levels was observed between stage 1 tumours and stages 2 (standardized mean difference [SMD], -0.51; 95 percent CI, -0.75 to -0.27; p<0.001), 3 (SMD, -0.83; -1.44 to -0.21; p=0.009) and 4 (SMD, -1.51; -2.59 to -0.42; p=0.006) tumours.

Ang-2 serum levels were also significantly different between stage 2 tumours and stages 3 (SMD, -0.52; -0.80 to -0.244; p<0.001) and 4 (SMD, -1.21; -1.98 to -0.44; p=0.002) tumours. Stages 3 and 4 tumours also differ in Ang-2 levels (SMD, -0.58; -0.93 to -0.23; p=0.001).

Serum Ang-2 concentrations were also significantly higher in lung cancer patients with lymph node involvement (SMD, 1.06; 0.57 to 1.56; p<0.001).

The role of Ang-2 on disease prognosis was examined in seven studies which included 575 patients. In these, significantly worse prognosis was associated with high serum Ang-2 levels (hazard ratio [HR], 1.64; 1.20 to 2.25; p=0.002).

Subgroup analysis by type of lung cancer showed that elevated Ang-2 levels were a risk factor for poor prognosis in patients with non-small cell lung cancer (HR, 1.44; 1.07 to 1.93; p=0.017) and small cell lung cancer (HR, 2.29; 1.46 to 3.59; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.